drugset / Trial / NCT00059813
Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer
NaSingle-groupOpen-labelTreatment
Summary
Phase II trial to study the effectiveness of combining oblimersen with interferon alfa in treating patients who have metastatic renal cell (kidney) cancer. Interferon alfa may interfere with the growth of tumor cells. Oblimersen may increase the effectiveness of interferon alfa by making tumor cells more sensitive to the drug.
Timeline
- Start
- 2003-08
- Primary completion
- 2005-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | oblimersen sodium | Antisense oligonucleotide | — | Intravenous |
| Subject | recombinant interferon alfa | Protein / enzyme biologic | — | Subcutaneous |